In summary, EMPA activates NRF1 and SIRT7, reduces lipid accumulation, improves insulin resistance, and suppresses oxidative stress in an HFD-fed mouse model of MASLD. Here, SIRT7 is linked to metabolic dysfunction-associated steatotic liver disease.